Childrens Mercy Hospital
- Type
- Teaching hospital
- Where
- KANSAS CITY, MO
- Medicare CCN
- 263302
- Received
- $4,101,213 in 634 records, 2025 ($225,191 general, $3,876,021 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE CHILDRENS MERCY HOSPITAL CORPORATION Fuzzy (name and state)
- Federal award recipient: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
- Nonprofit: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 27 | $225,191 |
| 2025 | Research payment | 607 | $3,876,021 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 607 | $3,876,021 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 6 | $102,195 |
| Consulting Fee | 3 | $90,000 |
| Long term medical supply or device loan | 8 | $23,521 |
| Space rental or facility fees (teaching hospital only) | 6 | $4,550 |
| Grant | 1 | $4,000 |
| Education | 1 | $700 |
| Charitable Contribution | 2 | $225 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Stryker Corporation | $8,652 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $1,941 | Research payment | In-kind items and services | Biological, ONCOLOGY | LIGHTBEAM-U01 Substudy 01C# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatr | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $1,168 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | LIGHTBEAM-U01 Substudy 01A# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatri | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $449 | Research payment | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $393 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | LIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit | 2025 |
| 2025-12-31 | Masimo Corporation | $142 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-12-31 | Masimo Corporation | $142 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-12-31 | Masimo Corporation | $142 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-12-31 | Masimo Corporation | $142 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-12-31 | Fisher & Paykel Healthcare Inc | $65 | Long term medical supply or device loan | In-kind items and services | FISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier | 2025 | |
| 2025-12-24 | Edwards Lifesciences Corporation | $4,590 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2025 |
| 2025-12-24 | Edwards Lifesciences Corporation | $3,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2025 |
| 2025-12-24 | Edwards Lifesciences Corporation | $854 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2025 |
| 2025-12-24 | Edwards Lifesciences Corporation | $531 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2025 |
| 2025-12-22 | Bayer Healthcare Pharmaceuticals Inc. | $4,120 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of | 2025 |
| 2025-12-22 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2025 |
| 2025-12-22 | Novo Nordisk AS | $150 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2025 |
| 2025-12-18 | ALBIREO PHARMA, INC. | $1,000 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2025 |
| 2025-12-16 | SANOFI PASTEUR INC. | $44,000 | Research payment | Cash or cash equivalent | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle | 2025 | |
| 2025-12-16 | Gilead Sciences, Inc. | $2,339 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2025 |
| 2025-12-16 | Gilead Sciences, Inc. | $264 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2025 |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $5,737 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $4,590 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Genentech, Inc. | $2,276 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | A PHASE 1 2 TRIAL OF GLOFITAMAB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH R R B NHL | 2025 |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $967 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $733 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $410 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $307 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $116 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $93 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $90 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $83 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $58 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-15 | Rhythm Pharmaceuticals, Inc. | $41 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-12 | Medtronic, Inc. | $12,960 | Long term medical supply or device loan | In-kind items and services | INVOS Device, Cerebral/Somatic Oximetry | 2025 | |
| 2025-12-12 | Rhythm Pharmaceuticals, Inc. | $3,352 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-12 | Rhythm Pharmaceuticals, Inc. | $3,352 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-12 | Rhythm Pharmaceuticals, Inc. | $3,352 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-12 | Rhythm Pharmaceuticals, Inc. | $2,734 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-12 | Rhythm Pharmaceuticals, Inc. | $2,734 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-12 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-12 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-09 | Travere Therapeutics, Inc. | $4,335 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2025 | |
| 2025-12-08 | Ultragenyx Pharmaceutical Inc. | $71,922 | Research payment | Cash or cash equivalent | GTX-102-CL301 | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $3,442 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $2,295 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $998 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $506 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $420 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $256 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $205 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $205 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $125 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $58 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-05 | Rhythm Pharmaceuticals, Inc. | $41 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-01 | Ultragenyx Pharmaceutical Inc. | $2,141 | Research payment | Cash or cash equivalent | GTX-102-CL301 | 2025 | |
| 2025-12-01 | Travere Therapeutics, Inc. | $1,362 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2025 | |
| 2025-12-01 | Rhythm Pharmaceuticals, Inc. | $70 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-01 | Rhythm Pharmaceuticals, Inc. | $60 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-01 | Rhythm Pharmaceuticals, Inc. | $55 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-01 | Rhythm Pharmaceuticals, Inc. | $55 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-01 | Rhythm Pharmaceuticals, Inc. | $32 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-01 | Rhythm Pharmaceuticals, Inc. | $24 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-12-01 | Rhythm Pharmaceuticals, Inc. | $3 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-25 | Ultragenyx Pharmaceutical Inc. | $1,696 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-11-25 | Ultragenyx Pharmaceutical Inc. | $1,350 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-11-25 | Ultragenyx Pharmaceutical Inc. | $1,350 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-11-25 | Ultragenyx Pharmaceutical Inc. | $1,174 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-11-25 | Ultragenyx Pharmaceutical Inc. | $1,128 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-11-25 | Ultragenyx Pharmaceutical Inc. | $364 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-11-20 | Rhythm Pharmaceuticals, Inc. | $3,442 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-20 | Rhythm Pharmaceuticals, Inc. | $1,012 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-20 | Rhythm Pharmaceuticals, Inc. | $307 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-20 | Rhythm Pharmaceuticals, Inc. | $280 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-20 | Rhythm Pharmaceuticals, Inc. | $90 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-20 | Rhythm Pharmaceuticals, Inc. | $41 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-19 | Edwards Lifesciences Corporation | $4,590 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2025 |
| 2025-11-19 | Edwards Lifesciences Corporation | $3,600 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2025 |
| 2025-11-19 | Edwards Lifesciences Corporation | $569 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2025 |
| 2025-11-19 | Edwards Lifesciences Corporation | $354 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2025 |
| 2025-11-18 | ACADIA Pharmaceuticals Inc | $389 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-303 | 2025 |
| 2025-11-18 | ACADIA Pharmaceuticals Inc | $90 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-11-14 | Azurity Pharmaceuticals, Inc. | $40 | Research payment | Cash or cash equivalent | FERAHEME Drug, HEMATOLOGY | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHA | 2025 |
| 2025-11-12 | Gen-Probe, Inc. | $97,488 | Research payment | Cash or cash equivalent | PANTHER FUSION Device, Diagnostics | Comparison of nasal swab and nasopharyngeal swab for respiratory testing using Hologic Panther Fusion assay | 2025 |
| 2025-11-06 | ALBIREO PHARMA, INC. | $800 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary A | 2025 |
| 2025-11-06 | ALBIREO PHARMA, INC. | $550 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2025 |
| 2025-11-05 | Rhythm Pharmaceuticals, Inc. | $270 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-05 | Rhythm Pharmaceuticals, Inc. | $70 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-05 | Rhythm Pharmaceuticals, Inc. | $32 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-11-04 | Ultragenyx Pharmaceutical Inc. | $180,398 | Research payment | Cash or cash equivalent | GTX-102-CL301 | 2025 | |
| 2025-11-04 | Bayer Healthcare Pharmaceuticals Inc. | $690 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of | 2025 |
| 2025-11-03 | Ultragenyx Pharmaceutical Inc. | $2,914 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-10-30 | ALBIREO PHARMA, INC. | $1,253 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2025 |
| 2025-10-30 | ALBIREO PHARMA, INC. | $1,050 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2025 |
| 2025-10-29 | Novo Nordisk AS | $2,388 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2025 |
| 2025-10-29 | Novo Nordisk AS | $1,797 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4467 | 2025 |
| 2025-10-29 | Novo Nordisk AS | $1,763 | Research payment | Cash or cash equivalent | Alhemo Drug, Hemophilia | NN7415-4807 | 2025 |
| 2025-10-28 | ABBVIE INC. | $3,250 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy | 2025 |
| 2025-10-28 | Gilead Sciences, Inc. | $3,041 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2025 |
| 2025-10-28 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy | 2025 |
| 2025-10-28 | ABBVIE INC. | $350 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy | 2025 |
| 2025-10-27 | Ionis Pharmaceuticals, Inc. | $26,798 | Research payment | Cash or cash equivalent | ION582P3 | 2025 | |
| 2025-10-27 | Ionis Pharmaceuticals, Inc. | $4,725 | Research payment | Cash or cash equivalent | ION582P3 | 2025 | |
| 2025-10-27 | Ionis Pharmaceuticals, Inc. | $3,645 | Research payment | Cash or cash equivalent | ION582P3 | 2025 | |
| 2025-10-27 | Ionis Pharmaceuticals, Inc. | $2,363 | Research payment | Cash or cash equivalent | ION582P3 | 2025 | |
| 2025-10-27 | Ionis Pharmaceuticals, Inc. | $675 | Research payment | Cash or cash equivalent | ION582P3 | 2025 | |
| 2025-10-25 | Edwards Lifesciences Corporation | $5,100 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2025 |
| 2025-10-25 | Edwards Lifesciences Corporation | $2,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2025 |
| 2025-10-25 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2025 |
| 2025-10-25 | Edwards Lifesciences Corporation | $177 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2025 |
| 2025-10-23 | Bayer Healthcare Pharmaceuticals Inc. | $520 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of | 2025 |
| 2025-10-23 | Azurity Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | FERAHEME Drug, HEMATOLOGY | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHA | 2025 |
| 2025-10-22 | SANOFI US SERVICES INC. | $5,500 | Research payment | Cash or cash equivalent | TZIELD Biological, Endocrine & Metabolic Diseases | A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a | 2025 |
| 2025-10-21 | Gilead Sciences, Inc. | $3,041 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2025 |
| 2025-10-17 | National Marrow Donor Program | $4,405 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-14 | SANOFI PASTEUR INC. | $69,000 | Research payment | Cash or cash equivalent | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to | 2025 | |
| 2025-10-14 | Dexcom, Inc. | $43,102 | Research payment | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2025 |
| 2025-10-14 | ALBIREO PHARMA, INC. | $15,520 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2025 |
| 2025-10-14 | ACADIA Pharmaceuticals Inc | $14,114 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-303 | 2025 |
| 2025-10-14 | ACADIA Pharmaceuticals Inc | $3,404 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-10-14 | Dexcom, Inc. | $2,280 | Research payment | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2025 |
| 2025-10-14 | ALBIREO PHARMA, INC. | $585 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2025 |
| 2025-10-09 | ALBIREO PHARMA, INC. | $1,237 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2025 |
| 2025-10-08 | Rhythm Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-08 | Rhythm Pharmaceuticals, Inc. | $1,012 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-08 | Rhythm Pharmaceuticals, Inc. | $205 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-08 | Rhythm Pharmaceuticals, Inc. | $90 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-08 | Rhythm Pharmaceuticals, Inc. | $70 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-08 | Rhythm Pharmaceuticals, Inc. | $70 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-08 | Rhythm Pharmaceuticals, Inc. | $68 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-08 | Rhythm Pharmaceuticals, Inc. | $41 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-08 | Rhythm Pharmaceuticals, Inc. | $31 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-03 | Ultragenyx Pharmaceutical Inc. | $4,050 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-10-03 | Ultragenyx Pharmaceutical Inc. | $1,012 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-10-03 | Ultragenyx Pharmaceutical Inc. | $909 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-10-03 | Ultragenyx Pharmaceutical Inc. | $36 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $3,352 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $3,352 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $3,114 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $3,114 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $3,114 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $3,114 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $3,114 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $2,720 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-02 | ABBVIE INC. | $2,327 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy | 2025 |
| 2025-10-02 | Rhythm Pharmaceuticals, Inc. | $972 | Research payment | Cash or cash equivalent | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $270 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $270 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $270 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $270 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $270 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $270 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $110 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $55 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $55 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $30 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $24 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $24 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $15 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $15 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-10-01 | Rhythm Pharmaceuticals, Inc. | $15 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-09-29 | SANOFI PASTEUR INC. | $11,500 | Research payment | Cash or cash equivalent | A Phase IIb, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an RSV Vaccine | 2025 | |
| 2025-09-25 | Edwards Lifesciences Corporation | $9,690 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2025 |
| 2025-09-25 | Edwards Lifesciences Corporation | $4,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2025 |
| 2025-09-25 | ALBIREO PHARMA, INC. | $2,436 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary A | 2025 |
| 2025-09-25 | ALBIREO PHARMA, INC. | $600 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2025 |
| 2025-09-25 | Bayer Healthcare Pharmaceuticals Inc. | $520 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of | 2025 |
| 2025-09-25 | Edwards Lifesciences Corporation | $300 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2025 |
| 2025-09-25 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2025 |
| 2025-09-25 | Edwards Lifesciences Corporation | $177 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2025 |
| 2025-09-24 | UCB Biosciences Inc. | $15,595 | Research payment | Cash or cash equivalent | Fintepla Drug, Neurology | Evaluating the safety of fenfluramine (Fintepla) for Dravet syndrome, Lennox-Gastaut syndrome, and other epilepsy patien | 2025 |
| 2025-09-24 | ACADIA Pharmaceuticals Inc | $5,941 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-09-24 | ACADIA Pharmaceuticals Inc | $5,400 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-09-24 | ACADIA Pharmaceuticals Inc | $914 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-09-24 | ACADIA Pharmaceuticals Inc | $682 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-09-24 | ACADIA Pharmaceuticals Inc | $299 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-09-24 | ACADIA Pharmaceuticals Inc | $90 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-09-24 | ACADIA Pharmaceuticals Inc | $82 | Research payment | Cash or cash equivalent | ACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROME | ACP-101-302 | 2025 |
| 2025-09-23 | Ultragenyx Pharmaceutical Inc. | $2,569 | Research payment | Cash or cash equivalent | UX143-CL301 | 2025 | |
| 2025-09-22 | SANOFI PASTEUR INC. | $66,700 | Research payment | Cash or cash equivalent | A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different Formulations | 2025 | |
| 2025-09-22 | Travere Therapeutics, Inc. | $40 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2025 | |
| 2025-09-20 | Rhythm Pharmaceuticals, Inc. | $240 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 | |
| 2025-09-20 | Rhythm Pharmaceuticals, Inc. | $49 | Research payment | In-kind items and services | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | 2025 |
The latest 200 records of 634.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Kansas City, MO | County Jackson County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 510,612 | 719,976 | 6,191,814 |
| Population, 2020 census P1 | 508,090 | 717,204 | 6,154,913 |
| Median age B01002 | 35.8 | 37.0 | 39.0 |
| Under 18 B01001 | 22.5% | 23.3% | 22.3% |
| 65 and over B01001 | 14.3% | 15.9% | 17.9% |
| Households B11001 | 221,979 | 306,798 | 2,508,227 |
| Foreign born B05002 | 8.6% | 6.6% | 4.5% |
| Median household income B19013 | $69,166 | $68,577 | $70,702 |
| Median family income B19113 | $92,934 | $90,585 | $91,360 |
| Per capita income B19301 | $41,393 | $39,559 | $39,695 |
| Poverty rate B17001 | 14.6% | 14.1% | 12.6% |
| Unemployment rate B23025 | 4.4% | 4.7% | 4.0% |
| Civilian labor force B23025 | 279,828 | 381,433 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.7 | 23.4 | 23.5 |
| Bachelor's degree or higher B15003 | 38.4% | 34.0% | 32.4% |
| Housing units B25001 | 245,346 | 336,288 | 2,825,287 |
| Owner-occupied B25003 | 55.4% | 59.1% | 68.1% |
| Renters B25003 | 44.6% | 40.9% | 31.9% |
| Median home value B25077 | $242,900 | $230,500 | $230,300 |
| Median gross rent B25064 | $1,238 | $1,197 | $1,033 |
| White, not Hispanic B03002 | 54.0% | 59.3% | 76.3% |
| Black B03002 | 25.2% | 22.0% | 10.9% |
| Hispanic or Latino B03002 | 12.5% | 11.4% | 5.2% |
| Asian B03002 | 2.8% | 1.8% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.
Comments